



- Primary Prevention Trial results I. Reduction in incidence of coronary heart disease. *JAMA* 1984; 251:351–364.
12. **Shepherd J, Cobbe SM, Ford I, et al for the West of Scotland Coronary Prevention Study Group.** Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia. *N Engl J Med* 1994; 333:1301–1307.
  13. **Sacks FM, Tonkin AM, Shepherd J, et al.** Effect of pravastatin on coronary disease events in subgroups defined by coronary risk factors: the Prospective Pravastatin Pooling Project. *Circulation* 2000; 102:1893–1900.
  14. **Waters DD, Guyton JR, Herrington DM, et al; TNT Steering Committee Members and Investigators.** Treating to New Targets (TNT) Study: does lowering low-density lipoprotein cholesterol levels below currently recommended guidelines yield incremental clinical benefit? *Am J Cardiol* 2004; 93:154–158.
  15. **Colhoun HM, Betteridge DJ, Durrington PN, et al; CARDS investigators.** Primary prevention of cardiovascular disease with atorvastatin in type 2 diabetes in the Collaborative Atorvastatin Diabetes Study (CARDS): multicentre randomised placebo-controlled trial. *Lancet* 2004; 364:685–696.
  16. **Neaton JD, Blackburn H, Jacobs D, et al.** Serum cholesterol level and mortality findings for men screened in the Multiple Risk Factor Intervention Trial. *Multiple Risk Factor Intervention Trial Research Group. Arch Intern Med* 1992; 152:1490–1500.
  17. **Ridker PM.** High-sensitivity C-reactive protein: potential adjunct for global risk assessment in the primary prevention of cardiovascular disease. *Circulation* 2001; 103:1813–1818.
  18. **Ridker PM, Rifai N, Rose L, Buring JE, Cook NR.** Comparison of C-reactive protein and low-density lipoprotein cholesterol levels in the prediction of first cardiovascular events. *N Engl J Med* 2002; 347:1557–1565.
  19. **Stampfer MJ, Manilow MA, Willett WC, et al.** A prospective study of plasma homocyst(e)ine and risk of myocardial infarction in US physicians. *JAMA* 1992; 268:877–881.
  20. **Gerstein HC, Mann JF, Yi Q, et al.** Albuminuria and risk of cardiovascular events, death, and heart failure in diabetic and nondiabetic individuals. *JAMA* 2001; 286:421–426.

**ADDRESS:** Julie Huang, MD, Section of Preventive Cardiology, C51, Department of Cardiovascular Medicine, The Cleveland Clinic Foundation, 9500 Euclid Avenue, Cleveland, OH 44195; e-mail [huangj1@ccf.org](mailto:huangj1@ccf.org).

## CORRECTION

### Parkinson-plus syndromes

(January 2005)

A typographic error appeared in the article “A 46-year-old woman with rigidity and frequent falls” by Drs. Babak Tousi, Stephan Schuele, and Thyagarajan

Subramanian in the January 2005 issue (*Cleve Clin J Med* 2005; 72:57–63). On page 58, first column, sixth paragraph in the section “Hypokinetic syndromes,” the first sentence should read “Our patient’s motor examination shows features of a hypokinetic syndrome” (not hyperkinetic, as printed).